

Research article

Antigen Detection in Urine Specimens from Dogs with Blastomycosis: Comparison of Rabbit Antibodies Prepared from a Human and Dog Isolate of *Blastomyces dermatitidis*

Janet Braun, Kristen Counsell, Chad Davis, Shailey Twamley, and Gene M. Scalarone

Department of Biological Sciences, Idaho State University, Pocatello, Idaho, USA

E-mail: braujane@isu.edu



This work is licensed under a [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/).

Abstract

Laboratory diagnosis of blastomycosis has relied on antibody detection assays for many years. During the past few years investigators have concentrated on developing improved assays for laboratory detection of antigen for this disease. This present study used a competitive enzyme-linked immunosorbent assay (ELISA) to compare antibodies prepared from killed whole yeast cells of *Blastomyces dermatitidis* isolates B5896 (Minnesota, human) and ERC-2 (Wisconsin dog) for the detection of antigen in urine specimens from 52 dogs with blastomycosis. The sensitivity ranged from 86.5% with B5896 antibody to 67.3% with the ERC-2 antibody. This comparative assay indicated that the B5896 antibody had a higher degree of sensitivity than ERC-2 antibody and seems to show potential for the reliable diagnosis of blastomycosis in humans and animals.

Key words: *Blastomyces dermatitidis*, antigen detection, ELISA, dog urine specimens, lysate antigens

Introduction

Blastomyces dermatitidis is a thermally dimorphic fungus that initially produces a pulmonary disease in humans and animals. It exists as a mold in moist environments and mainly found in states surrounding the Mississippi and Ohio Rivers and the disease is also endemic in Wisconsin and Minnesota plus areas of southern Canada [1-3].

The mycelial phase of the fungus produces microscopic spores or conidia that are the infectious agents that enter the host via the respiratory system. In the host the fungus has the unique ability to convert into a budding yeast cell that may remain in the lungs or it may progress to an invasive disease and cause a serious or fatal infection. Dissemination often results in bone, central nervous system and skin involvement [4-7].

The laboratory diagnosis of blastomycosis relies on a combination of clinical history, cytologic/histologic visualization of the yeast cells or by immunodiagnostic methods to detect antibody or antigen in clinical specimens. In certain instances these methods may prove to be inadequate and could result in a non-diagnosis or a misdiagnosis as another microbial disease. Therefore investigators have concentrated on developing improved immunodiagnostic methods that will provide for rapid and reliable results [6-14]. Antibody detection assays have been faced with sensitivity and specificity problems, but researchers working on antigen detection assays have shown the potential of these assays to provide valuable diagnostic results in both histoplasmosis and blastomycosis [8-14].

Our laboratory has been involved in the utilization of different polyclonal antibodies, produced in rabbits from various *B. dermatitidis* yeast lysates or killed whole yeast cells, for the detection of antigen in urine specimens from dogs with diagnosed blastomycosis [16-18].

Our present project was designed to evaluate and compare antibodies produced in rabbits immunized with *B. dermatitidis* killed whole yeast cells from isolates (B5896, human isolate, Minnesota; ERC-2, dog isolate, Wisconsin) for antigen detection in urine specimens from dogs as above.

Materials and Methods

Antibodies

The antibodies were obtained from rabbits immunized with B5896 (Minnesota, human) and ERC-2 (Wisconsin dog) *B. dermatitidis* killed whole yeast cells. The rabbits were housed in accordance to the NIH guide for Care and Use of Laboratory Animals with approval from the Idaho State University IACUC.

Urine Specimens

Fifty- two urine specimens were provided by Dr. A.M. Legendre (University of Tennessee College of Veterinary Medicine, Knoxville, TN).

Competitive ELISA method

The horseradish peroxidase competitive binding inhibition ELISA was used for the detection of *B. dermatitidis* antigens in the urine specimens. Microdilution plates (96 well NUNC, Thermo-Fisher) were coated with 100 μ l of B5896 (Minnesota human isolate) lysate antigen that was diluted (2000 ng ml⁻¹) in a carbonate-bicarbonate coating buffer (pH 9.6). The plates were incubated overnight at 4° C in a humid chamber followed by washing three times with phosphate buffered saline containing 0.15% Tween 20 (PBS-T). Dog urine and 1:2200 antibody obtained from rabbits immunized with either B5896 (Minnesota human) or ERC-2 (Wisconsin dog) were added to microcentrifuge tubes (200 μ l plus 200 μ l of each urine specimen) and incubated for 30 min at 37° C. Following this incubation step 100 μ l of the antibody-urine mixture from the microdilution tubes was added to the above plates containing the B5896 antigen and incubated for 30 min at 37° C. The plates were again washed as above and 100 μ l of goat anti-rabbit IgG horseradish peroxidase conjugate (Kirkegaard and Perry Laboratories, KPL) was added to each well and incubated for 30 min at 37° C and were washed as above. Then 100 μ l of Sure BlueTMB peroxidase substrate (KPL) was added to each well and incubated for approximately 2 min at room temperature. Stop Solution (KPL) was added to each well and the absorbance was read using a BIO-RAD 2550 EIA reader at 450 nm. Positive controls containing known B5896 antigen coated on the plate and the above sera from the immunized rabbits were used to determine the baseline value to which all of the urine specimens were compared.

Results/Discussion




Figure 1. The specimens were from 52 dogs that were infected with *B. dermatitidis*. The horizontal line represents the control. Any result that is above the control line shows that no antigen was detected. This figure shows 86.5% antigen detection with the Competitive ELISA.




Figure 2. The specimens were from 52 dogs that were infected with *B. dermatitidis*. The horizontal line represents the control. Any result that is above the control line shows that no antigen was detected. This figure shows 67.3% antigen detection with the Competitive ELISA.

B5896 antibody detected antigen in 45 out of 52 (86.5%) urine samples from dogs diagnosed with *B. dermatitidis* infections. As Figure 1 shows, the control value was 1.059 and the absorbance value range of antigen detection was 0.4015 – 1.486, values below the control line indicate antigen detection. In contrast the ERC-2 antibody detected antigen in 35 out of 52 (67.3%) specimens. Figure 2 shows the control value was 0.83 and the absorbance value range of antigen detection was 0.1165 – 1.207. Comparing the sensitivity of B5896 antibody and ERC-2 antibody, the B5896 antibody was more effective in detecting *B. dermatitidis* antigen in dog urine than the ERC-2 by 20%.

Many studies have been done pertaining to antibody detection in individuals diagnosed with blastomycosis. This approach has been unsuccessful at diagnosing blastomycosis in immunocompromised individuals because of their inability to produce antibodies. However the detection of antigen presents another option for laboratory diagnostic tests of *B. dermatitidis* infections. Studies are continuing to evaluate antibodies produced by various strains of *B. dermatitidis*.

Acknowledgements

This research was supported through the Department of Biological Sciences at Idaho State University, Pocatello, Idaho, USA.

References

- [1] A.F. DiSalvo, "Blastomycosis", in *Topley and Wilson's Microbiology and Microbial Infections*, L. Collier, ed., pp. 337-355, Arnold Publishers, London, UK, 9th edition, 1998.
- [2] M.A. Pfaller and D.J. Diekema, "Epidemiology of invasive mycoses in North America. *Critical Reviews in Microbiology*, vol. 36, no.1, pp. 1-53, 2010.
- [3] K. Benedict, M. Roy, T. Chiller and J.P. Davis, "Epidemiologic and ecologic features of blastomycosis: A review," *Curr Fungal Infect Rep*, Vol 6, pp. 327-335, 2012.
- [4] R.W. Bradsher, "The endemic mimic: Blastomycosis and illness often misdiagnosed," *Transactions of the American Clinical and Climatological Association*, Vol. 125, pp. 188-203, 2014.
- [5] J.R. Bariola and K.S. Vyas, "Pulmonary Blastomycosis," *Seminars in Respiratory Critical Care Medicine*, Vo. 32, No. 6, pp. 745-753, 2011.
- [6] M. Saccente and G.L. Woods, "Clinical and Laboratory Update on Blastomycosis," *Clinical Microbiology Reviews*, Vol. 23, No. 2, pp. 367-381, 2010.
- [7] J.A. McKinnell and P.G. Pappas, "Blastomycosis: New Insights into Diagnosis, Prevention, and Treatment," *Clinical Chest Medicine*, Vol. 30, pp. 227-239, 2009.
- [8] D. Spector, A.M. Legendre, J. Wheat, D. Bemis, B. Rohrbach, J. Taboada and M. Durkin, "Antigen and Antibody Testing for the Diagnosis of Blastomycosis in Dogs," *Journal of Veterinary Internal Medicine*, Vol. 22, pp. 839-843, 2008.
- [9] K.S. Vyas, J.R. Bariola and R.W. Bradsher, "Advances in the Serodiagnosis of Blastomycosis," *Current Fungal Infection Reports*, Vol. 2, pp. 227-231, 2008.
- [10] J.R. Bariola, C.A. Hage, M.E. Durkin, E. Bensadoun, P.O. Gubbins, L.J. Wheat and R.W. Bradsher, "Detection of *Blastomyces dermatitidis* Antigen in Patients with Newly Diagnosed Blastomycosis," *Diagnostic Microbiology and Infectious Diseases*, Vol. 69, No.2, pp. 187-191, 2011.
- [11] P. Connolly, C.A. Hage, J.R. Bariola, E. Bensadoun, M. Rodgers, R.W. Bradsher, and J.J. Wheat, "Blastomyces dermatitidis Antigen Detection by Quantitative Enzyme Immunoassay," *Clinical Vaccine Immunology*, Vol. 19, No. 1, pp. 53-56, 2012.
- [12] C.A. Hage, T.E. Davis, L. Egan, M. Parker, D. Fuller, A.M. LeMonte, D. Durkin, P. Connelly, L.J. Wheat, D. Blue-Hindy and K.A. Knox, "Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzyme-linked immunoassay," *Respiratory Medicine*, Vol. 10, pp. 43-47, 2007.
- [13] E.S. Theel, D.J. Jespersen, J. Haring, J. Mandrekar and M.J. Binnicker, "Evaluation of an Enzyme immunoassay for detection of *Histoplasma capsulatum* from urine specimens," *Journal of Clinical Microbiology*, Vol. 51, No. 11, pp. 3555-3559, 2013.

- [14] D.S. Foy, L.A. Trepanier, E.J. Kirsch and L.J. Wheat, "Serum and urine *Blastomyces* antigen concentrations as markers of clinical remission in dogs treated for systemic blastomycosis." *J Vet Intern Med*, 10.1111/jvim.12306, 2014.
- [15] S.M. Johnson and G.M. Scalalone, "Preparation and ELISA Evaluation of *Blastomyces dermatitidis* Yeast Phase Lysate Antigens," *Diagnostic Microbiology and Infectious Diseases*, Vol. 11, pp. 81-86, 1989.
- [16] J.F. Shurley, A.M. Legendre and G.M. Scalalone, "*Blastomyces dermatitidis* Antigen Detection in Urine Specimens from Dogs with Blastomycosis Using a Competitive Binding Inhibition ELISA," *Mycopathologia*, Vol. 160, No. 2, pp. 137-142, 2005.
- [17] D. Andrae, K. Birch, T. Bybee, T. Ritcher, J. Werth, and G.M. Scalalone, "Antigen Detection in Canine Blastomycosis: Comparison of Different Antibody-Antigen Combinations in Two Competitive ELISAs," *Open Journal of Medical Microbiology*, Vol. 2, pp. 110-114, 2012.
- [18] A. Searle and G.M. Scalalone, "Comparative antibody study for antigen detection in urine specimens for diagnosis of blastomycosis using a competitive enzyme-linked immunosorbent assay." *Open Journal of Immunology*, Vol. 2, No. 4, pp. 139-143, 2012.
- [19] G.M. Scalalone, H.B. Levine and S.D. Chaparas, "Delayed Hypersensitivity Responses of Experimental Animals to Histoplasmin from the Yeast and Mycelial Phases of *Histoplasma capsulatum*," *Infection and Immunity*, Vol. 21, pp. 705-713, 1978.
- [20] H.B. Levine, G.M. Scalalone and S.D. Chaparas, "Preparation of Fungal Antigens and Vaccines: Studies on *Coccidioides immitis* and *Histoplasma capsulatum*," *Contributions to Microbiology and Immunology*, Vol. 3, pp. 106-125, 1977.
- [21] H.B. Levine, G.M. Scalalone, G.D. Campbell, R.C. Graybill and S.D. Chaparas, "Histoplasmin-CYL, A Yeast Phase Reagent in Skin Test Studies in Humans," *American Review of Respiratory Diseases*, Vol. 119, pp. 629-636, 1979.